Keyword: Samsung Bioepis

China conditionally approves Merck's Gardasil 9; Biogen looks to up its stake in Samsung Bioepis; WuXi plots a series of major expansions; and more.

Ahead of a big launch this fall, Biogen says it plans to increase its stake in a biosimilars joint venture shared with Samsung.

Novartis faces doctor kickback allegations in China, Samsung and AbbVie ink a Humira biosim settlement, and Takeda seeks financing for a Shire bid.

J&J's Remicade fell victim to biosimilar competition in Europe and the U.S., but the copycats' impact has been quite different in the two regions.

J&J dropped a lawsuit accusing Samsung Bioepis of infringing patents on Remicade, a $5 billion med that now faces biosimilar rivals.

Samsung Bioepis has taken a big step toward approval for a Herceptin biosim in Europe.

Takeda and AZ will team up on Parkinson’s candidate, Samsung Bioepis got nod for a Humira copycat and Daiichi Sankyo said AZ buyout is “not the fact.”

The forces of competition are mounting against Humira, the world’s best-selling drug at $16 billion in global sales, with approval of a second biosimilar in Europe.

Samsung inked a novel drug R&D pact with Takeda, GSK China partnered with Alibaba on HPV vaccination, Gland is revising its M&A deal with Fosun.

Samsung launched Remicade biosimilar, Mitsubishi Tanabe bought NeuroDerm for $1.1 billion, Takeda made a drug discovery deal.